What are the effects and functions of osimertinib?

Osimertinib (Tagrisso) is a breakthrough anti-cancer drug with multiple functions and effects, which is particularly important in the treatment of non-small cell lung cancer (NSCLC). Osimertinib is a tyrosine kinase inhibitor used to treat certain types of non-small cell lung cancer.

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutated forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumors after first-line EGFR-TKI therapy. As a third-generation tyrosine kinase inhibitor, osimertinib is specific for the gating T790M mutation, which increases ATP binding activity to EGFR and leads to poor prognosis in advanced disease. Additionally, osimertinibhas been shown to bypass wild-type EGFR during treatment, thereby reducing nonspecific binding and limiting toxicity. Compared with wild-type EGFR, osimertinib has a 200-fold higher affinity for EGFR molecules harboring the L858R/T790M mutation in vitro.

In addition, compared with traditional chemotherapy drugs, osimertinib has relatively fewer side effects, thanks to its targeted therapy properties. It can act on tumor cells more accurately and reduce toxicity to normal cells, thereby improving patients' quality of life.

In general, osimertinib brings new treatment hope to patients with non-small cell lung cancer due to its uniqueEGFR inhibitory ability and targeting of drug-resistant mutations. Its significant anti-tumor effect, ability to control CNS metastasis, and relatively minor side effects make osimertinib a shining pearl in modern anti-cancer treatment. By taking osimertinib, patients can not only prolong their survival, but also maintain a better quality of life to a certain extent. This is undoubtedly a huge boon for patients brought by medical advancement.